OPEN ACCESS

CONCISE REPORT

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

Monika M Schoels,¹ Désirée van der Heijde,² Ferdinand C Breedveld,² Gerd R Burmester,³ Maxime Dougados,⁴ Paul Emery,⁵ Gianfranco Ferraccioli,⁶ Cem Gabay,⁷ Allan Gibofsky,⁸ Juan Jesus Gomez-Reino,⁹ Graeme Jones,¹⁰ Tore K Kvien,¹¹ Miho M Murikama,¹² Norihiro Nishimoto,¹² Josef S Smolen^{1,13}

► Additional supplementary files are published online only. To view these files please visit the journal online (<http://dx.doi.org/10.1136/annrheumdis-2012-202470>).

For numbered affiliations see end of article.

Correspondence to

Dr Monika M Schoels,
2nd Department of Internal
Medicine, Center for
Rheumatic Diseases, Hietzing
Hospital, Wolkersbergenstrasse
1, Vienna 1130, Austria;
monika.schoels@live.com

Accepted 14 October 2012
Published Online First
11 October 2012

ABSTRACT

Background Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications.

Objective To review published evidence on safety and efficacy of IL-6i in inflammatory diseases.

Methods We performed systematic literature searches in Medline and Cochrane, screened EULAR and American College of Rheumatology meeting-abstracts, and accessed <http://www.clinicaltrials.gov>.

Results Comprehensive evidence supports the efficacy of tocilizumab in RA in DMARD-naïve patients, and after DMARD- and TNFi-failure. Randomised comparisons demonstrate superiority of tocilizumab in JIA, but not ankylosing spondylitis (AS). Other indications are currently investigated. Additional IL-6i show similar efficacy; safety generally appears acceptable.

Conclusions IL-6i is effective and safe in RA and JIA, but not in AS. Preliminary results in other indications need substantiation.

INTRODUCTION

Therapeutic options for rheumatoid arthritis (RA) and other inflammatory diseases are rapidly increasing. In addition to synthetic disease modifying anti-rheumatic drugs (DMARDs), biological agents that selectively target either cell-bound structures or cytokines are now available. Among those, suppression of the IL-6 mediated pathway has been the most recently introduced treatment principle, confirming the role of IL-6 in the pathophysiology of inflammation.¹ The only agent currently approved for IL-6 inhibition is tocilizumab, an antibody to the IL-6-receptor, but other compounds targeting this structure or its ligand IL-6 are currently in development. In this review, we assemble the state of knowledge regarding IL-6 blocking therapy in inflammatory rheumatologic diseases.

METHODS

Data Sources and Searches: We performed a systematic literature research of electronic databases. Our initial search included publications of Medline and Cochrane, each from their inception to January 2012. We also searched abstract archives of European League Against Rheumatism (EULAR)² (2010–2012) and American College of Rheumatology (ACR)³ (2010 and 2011) conferences and accessed the National Institutes of Health database on clinical trials⁴ for preliminary results from on-going trials.

Study selection

By title and abstract screening, we evaluated all retrieved publications according to the inclusion-criteria. Online supplementary table S1 enlists the search terms and describes our approach regarding the population, intervention, control and outcomes.

Data synthesis

We performed meta-analyses of comparable randomised controlled trial (RCT) data, using Meta-Analyst software.⁵ We tested for heterogeneity among the included trials (Cochrane's Q) and present the results of a random effects model (DerSimonian Laird). We provide descriptive comparisons of non-randomised prospective trials and observational data.

Data Extraction, Quality Assessment: We extracted efficacy data on clinical, functional and radiographic outcomes as well as safety data from all included studies. We evaluated all RCTs according to the Jadad scoring system⁶ and followed PRISMA reporting guidelines.⁷ Some of the results are shown in the online supplementary file which is part and parcel of this publication.

RESULTS

We initially retrieved 3935 Medline and 39 Cochrane publications for screening, and selected 166 fulltext papers for inclusion in this review. Furthermore, we found 293 eligible abstracts from recent scientific meetings and incorporated results from four ongoing trials (<http://www.clinicaltrials.gov>) (figure 1).

Figure 1 Search and selection process. AoSD, adult onset Still's disease; ACR, American College of Rheumatology conference; CLE, cutaneous lupus erythematosus; EULAR, European League Against Rheumatism; IBD, inflammatory bowel disease; inhib., inhibitors; JIA, juvenile idiopathic arthritis; N, number; PMR, polymyalgia rheumatica; RA, rheumatoid arthritis; SpA, spondyloarthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.

Here we focus primarily on RA and tocilizumab, but also address other licensed and off-label indications and other compounds.

EFFICACY

Rheumatoid arthritis (RA)

Randomised comparisons demonstrated the efficacy of tocilizumab in DMARD-naïve patients,⁸ in insufficient responders (IR) to DMARDs,^{9–19} and in IR to TNF-inhibitors (TNFi).^{20–22} If not indicated otherwise, results of the 8 mg/kg dose, given intravenously 4-weekly, are reported. Outcomes are summarised in table 1. Quality scoring of RCTs is provided in online supplementary table S2.

Clinical outcomes

ACR20/50/70 responses at 24 weeks were 69/45/27% using tocilizumab monotherapy in DMARD-naïve patients, compared with 54/33/14% on methotrexate (MTX) monotherapy, and 56–80/30–64/4–44% (ACR20/50/70) in DMARD-IR, when compared with placebo-arms (usually continued or de novo MTX therapy, with ACR20/50/70 response rates of 17–34/21–26/2–20%). Finally, in TNFi-IR, tocilizumab achieved 50/27–29/10–12% (ACR20/50/70) at 24 weeks versus 10/4/1% in the MTX plus placebo-arm (tables 1 and S2). In a recently published small prospective study of patients receiving tocilizumab after failure of ≥ 2 DMARDs, one TNFi, and rituximab, 49/20% achieved EULAR good/moderate response.²³ Efficacy was sustained during long-term extensions (LTE) of several RCTs.^{24–27} Drug-free DAS28 remission rates were 35% 24 weeks after withdrawing tocilizumab and 13% 52 weeks thereafter²⁸ and tocilizumab re-treatment upon flares was

successful in the Japanese DREAM- and RESTORE studies.^{29–30} Patients can also maintain tocilizumab-free remission rates with continued MTX, as recently reported in sub-analyses of the OPTION-study.³¹

In the ACT-RAY-trial,¹⁷ MTX-IR were randomised to either tocilizumab monotherapy (withdrawing MTX), or tocilizumab added to MTX. A superior efficacy of the combination treatment could not be demonstrated in any of the clinical, functional or radiographic endpoints. These results have been confirmed in TNFi-IR.²² Figure 2A displays the risk ratios (RR) and CIs comparing tocilizumab monotherapy versus combination therapy in RCTs. Several non-randomised, open-label studies support the finding that mono- and combination therapy are similarly effective.^{32–35}

Physical function also improved significantly on tocilizumab as monotherapy^{8–12, 14–17} or combined with DMARDs.^{11–17, 20} 59–60% of patients achieved minimal clinical important difference of Health Assessment Questionnaire (HAQ) (defined ≥ 0.3 or 0.22) after 24 weeks,^{8–10, 11, 14–17, 20} 52% after 52 weeks,^{12–13} compared with 34–53% in the respective placebo groups (table 1).

Radiographic outcomes are available from the LITHE,¹³ SAMURAI¹² and ACT-RAY¹⁷ trials: tocilizumab in combination with MTX^{13–17} or monotherapy^{12–17} retarded radiographic progression after 24¹⁷ or 52 weeks.^{12–13} MRI data showed early and sustained suppression of synovitis and osteitis.^{36–38} During long-term follow-up, no radiographic progression after 3 years occurred in 67–69%.³⁹ Radiographic benefit was linked to decreased C-reactive protein and cartilage turnover markers.⁴⁰ Preliminary results indicate that tocilizumab also improves bone mineral density in RA^{41–42} (table 1).

Table 1 Tocilizumab: pivotal randomised controlled trials in rheumatoid arthritis

	Study: Name/ Author, PY	Previously failed	Comparators	Combi-nation	ACR20	ACR50	ACR70	HAQ (% ≥ MCID)	x-Ray	FU
TCZ in combination therapy	OPTION 2008 ¹¹	MTX	PL/TCZ 4/TCZ 8	MTX	26/48/59	11/31/44	2/12/22	47/61/59*	n.s.	24
	TOWARD 2008 ¹⁰	DMARD	PL/TCZ 8	DMARD	25/61	9/38	3/21	34/60*	n.s.	24
	RADIATE 2008 ¹⁹	TNFi	PL/TCZ 4/TCZ 8	MTX	10/30/50	4/17/29	1/5/12	Δ-0.4/-0.3/ -0.1	n.s.	24
	ROSE 2012 ²⁰	DMARD	PL/TCZ 8	DMARD		11/30		n.s.	n.s.	
monotherapy versus Combination	LITHE 2011 ¹³	MTX	PL/TCZ 4/TCZ 8	MTX	25/47/56	10/29/36	4/16/20	53/60/63*	1.1/0.3/0.3†	52
	NCT00106535 ¹⁸	MTX	PL / TCZ 4/TCZ 8	MTX	27/51/56	10/25/32	2/11/13	-0.3±0.5/-0.5 ±0.5/-0.5±0.6†	n.s. (yet)	24
	Lim 2012 ¹⁹	MTX	PL/TCZ 8	MTX	62/17	30/2	4/2	n.s.	n.s.	24
	CHARISMA 2006 ¹⁵	MTX	PL/2/4/8 TCZ-m vs. each dose TCZ-c + MTXHere: 4 m/4c/8m/ 8c	MTX	61/63// 63/74	28/37// 41/53	6/12// 16/37	n.s.	n.s.	16
TCZ monotherapy	ACT-RAY 2012 ¹⁷	MTX	TCZ 8 m/TCZ 8	MTX	71/72	41/45	26/25	33/33§	0.1(1.9)/0.2 (1.1)§	24
	NCT00891020 ²²	TNFi	TCZ 8 m / TCZ 4/TCZ 8	DMARD	48/45/50	25/24/27	7/9/10	n.s. (yet)	n.s. (yet)	24
	Choy 2002 ⁹	DMARD	PL/single i.v. dose of 0.1/1/5/ 10 mg MRA					n.s.	n.s.	2
	Nishimoto 2004 ¹⁶	DMARD	PL/TCZ 4/TCZ 8		57/78	26/40	20/16	n.s.	n.s.	12
	AMBITION 2010 ⁸	(67% MTX-naïve pts.)	MTX/TCZ 8		52/70 (54/69)	34/44 (33/45)	15/28 (14/27)	Δ-0.5/-0.7	n.s.	24
	SATORI 2009 ¹⁴	MTX	MTX/TCZ 8		25/80	11/49	6/30	34/67%¶	n.s.	24
	SAMURAI 2007 ¹²	DMARD	DMARDs/TCZ 8		34/78	13/64	6/44	40/68%¶	6.1 (4.2-8.0)/ 2.3 (1.5-3.2)	52

**

ACR, American College of Rheumatology; DMARD, disease modifying antirheumatic drug; FU, follow-up (weeks); MCID, minimally clinical important difference; MTX, methotrexate; PL, placebo; PY, year of publication; TCZ, tocilizumab; TCZ-m, tocilizumab-monotherapy; TCZ-c, tocilizumab in combination therapy; TNFi, tumour necrosis factor inhibitor; TNFi, tumour necrosis factor inhibitor *MCID HAQ>0.3.

†total Genant-modified Sharp Score (GTSS), mean change from BL.

§GTSS, BL annualised progression rate; mean (SD).

¶MCID HAQ≥0.22; Δ mean change from BL; GTSS, total Genant modified Sharp Score.

**vdH-TSS, mean (95%CI) change from baseline TCZ doses are abbreviated with '8'=8 mg/kg 4 weekly and '4'=4 mg/kg 4 weekly.

Dose

Superior efficacy of the 8 mg/kg 4-weekly dose was seen with regard to clinical responses in DMARD-IR^{11 13 18} and TNFi-IR.^{20 22} Figure 2B depicts the risk ratio (RR, and 95% CI) of ACR-responses with 8 mg/kg tocilizumab versus 4 mg/kg; overall, this difference is significant. Nevertheless, radiographic outcome was similar at both doses.¹³ This could indicate a dissociation between inflammation and damage by tocilizumab.⁴³

Some meta-analyses of trial data and observational studies suggest superior efficacy of tocilizumab combination with MTX in DMARD-IR when compared with TNFi, abatacept, and rituximab.⁴⁴⁻⁴⁷ However, one network meta-analysis reported higher response rates for etanercept and certolizumab.⁴⁸ In a meta-analysis of trials including TNFi-IR, outcomes of tocilizumab and abatacept, golimumab, and rituximab were similar.⁴⁹ Observational data confirmed these analyses showing similar efficacy of biologics combination therapy in TNFi-IR.⁵⁰ In the first available direct randomised comparison of biologics as monotherapy,⁵¹ tocilizumab was superior to adalimumab in DMARD-IR; however, TNFi monotherapy in general and particularly adalimumab are inferior to combination with MTX.⁵²

In conclusion, RCTs unanimously confirm efficacy of tocilizumab in RA, and non-randomised prospective studies^{35 53 54} observational studies^{45 55-59} and registry data^{60 61} corroborate this. Recently published reviews of tocilizumab in RA also confirm this conclusion.⁶² Tocilizumab is also effective as subcutaneous formulation.^{63 64}

Another substance directed against the IL-6-receptor, *sarilumab*, is in early phase trials.^{65 66} Agents that directly target IL-6 also

show promising preliminary results, among those, *sirukumab*,⁶⁷⁻⁶⁹ *B-E8*,⁷⁰ and *BMS-945429*, that demonstrated rapid and sustained ACR-response in MTX-IR.⁷¹⁻⁷³ Lastly, *olokizumab*, a humanised IL-6 antibody, is currently investigated in phase II dose-ranging studies^{74 75} for RA. Data are compiled in online supplementary table S4.

Juvenile Idiopathic Arthritis (JIA)

A number of randomised trials show efficacy in systemic JIA. These are summarised in online supplementary table S3.

Clinical response (ACR30pedi/50/70) to tocilizumab 8 mg/kg q2 weeks was 85/85/71% after 12 weeks;⁷⁶ sustained efficacy was seen during LTE with 88/89/65% ACR response rates after 1 year⁷⁷ and 88% (ACR70) and 71% (ACR90) after 2 years.⁷⁸ Remission rates were 67% over 3.5 years,⁷⁹ and 38% of patients had drug-free remission at 6 years.⁸⁰ Several studies also addressed IL-6i in poly- or oligoarticular JIA, and reported clinical success,⁸¹⁻⁸⁵ however, no randomised comparison in this patient population is available to date.

Other Indications

In *ankylosing spondylitis*, no benefit could be shown in randomised comparisons. Results are further elaborated in the online supplement. In this document, also data on case reports or small studies for various indications are expanded. Indications include *adult onset Still's disease*, *polymyalgia rheumatica*, *multifocal refractory vasculitis*, *relapsing polychondritis*, *Castleman's disease*, *systemic lupus erythematosus* and *systemic sclerosis*. In *Crohn's disease*, tocilizumab was clinically superior to placebo.

Figure 2 ACR20/50/70 response rates. (A) Comparison of tocilizumab monotherapy versus combination of tocilizumab with DMARDs. (B) Comparison of 4 mg/kg versus 8 mg/kg 4-weekly. Risk ratios and 95% CIs are displayed. RR > 1 favour combination therapy (in panel A) or the 4 mg/kg TCZ dose (in panel B). ACR, American College of Rheumatology

SAFETY

A Cochrane review of tocilizumab in RA reported 1.2x more frequent adverse events (AE) than for pooled placebo patients (74% vs 65%).⁸⁶ No significant difference in serious AE (SAE), or withdrawals due to AE was reported.⁸⁶ Retention rates have been repeatedly confirmed to be high,⁵⁵⁻⁵⁸ also suggesting acceptable safety. Cumulative safety data from RA trials, evaluating a total tocilizumab exposure of 8580 patient-years (PY),⁸⁷ yielded an AE rate of 278/100 PY and SAE rate of 14/100 PY. These results are consistent with LTEs and postmarketing surveillance showing incidence rates of 43–44%⁸⁸⁻⁸⁹ or 167 events/100 PY⁹⁰ (AE), and 9–10%⁸⁸⁻⁸⁹ or 27/100 PY²⁷⁻³⁰ (SAE). SAE increased with longer disease duration.⁸⁹ Comparing the safety profile of tocilizumab to other biologicals, a meta-analysis investigated TNFi, anakinra, abatacept, rituximab, and tocilizumab⁹¹ and showed similar rates of SAE, serious infections, lymphoma, and congestive heart failure. An indirect comparison of abatacept,

golimumab, and rituximab with tocilizumab in RA following TNFi-IR showed similar safety.⁵³

AE of tocilizumab and other IL-6i primarily comprise infections, neutropenia, thrombocytopenia, hyperlipidaemia, gastrointestinal AEs and liver enzyme increases; details are presented in the online supplement.

Myocardial Infarction and Stroke

Myocardial infarction and stroke rates of pooled RCT treatment groups were 0.25/100 PY and 0.19/100 PY versus 0.49/100 PY and 0.24/100 PY in the pooled control group; without increase over time.⁸⁷

PREGNANCY

No complications were noticed in registries.⁹²⁻⁹³ Recently, outcomes of all pregnancies occurring in any of the pivotal RA-RCTs or LTEs, covering 10 994 PY, were presented: 33

pregnancies resulted in 7 spontaneous and 13 therapeutic abortions and 11 normal deliveries.⁹⁴

DISCUSSION

Tocilizumab is an efficacious biologic agent and is acceptably safe in RA and JIA. The efficacy data relate to clinical and functional aspects of these diseases. In ankylosing spondylitis (AS), randomised comparisons did not show beneficial effects. In other diseases, preliminary data highlight the need for future research: inhibition of the IL-6 pathway seems to become an option for the treatment of several other inflammatory diseases, but conclusive RCT data are still lacking. Antibodies against the ligand IL-6 could soon augment the armamentarium for targeted treatment of RA and JIA and appear to have similar efficacy and safety profiles as IL-6 receptor inhibition.

Author affiliations

¹2nd Department of Medicine, Center for Rheumatic Disease, Hietzing Hospital, Vienna, Austria

²Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands

³Department of Rheumatology and Clinical Immunology, Charité, Free University and Humboldt University, Berlin, Germany

⁴Department of Rheumatology, Cochin Hospital, René Descartes University, Paris, France

⁵Academic Unit of Musculoskeletal Diseases, Leeds University, Leeds, UK

⁶Division of Rheumatology and Internal Medicine—CIC, Catholic University of the Sacred Heart—School of Medicine, Rome, Italy

⁷Division of Rheumatology, University Hospital, University of Geneva, Geneva, Switzerland

⁸Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York, USA

⁹Department of Rheumatology Unit, Hospital Clínico Universitario, Santiago de Compostela, Santiago

¹⁰Musculoskeletal Unit, Menzies Research Institute, University of Tasmania, Hobart, Australia

¹¹Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

¹²Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, Japan

¹³Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria

Acknowledgements This study was made possible by a grant from Roche. However, no representative of the company attended the meetings or was involved in the literature search.

Funding None.

Contributors All authors contributed and finally approved the current manuscript.

Competing interests DvdH: Consulting and/or speaking activities for and/or research grants from Roche/Chugai, BMS, Sanofi and Aventis; GB has been a consultant and speaker for Roche and BMS and has received grant support from Roche, BMS and Sanofi; MD received grant support from and has participated at advisory board meetings and symposia organised by Roche; PE has provided expert advice for Roche, BMS, Lilly, Sanofi and undertaken clinical trials for Roche and BMS; GFF has received speaking fees and research grants from Roche; CG received consultant/speakers fees from Roche and BMS; AG has been a consultant and speaker for Roche/Genentech and holds shares of BMS; JJGR received grant support from and has participated at advisory board meetings and symposia organised by Roche; GJ has received grant support given talks and served on advisory boards for Roche; TKK received grant support from and/or has participated at advisory board meetings and/or symposia organised by Roche, BMS, UCB; NN has received speaking, consulting fees and/or research grants from Chugai/Roche and BMS; NB's company has received income for services delivered to Roche; JSS received grant support from and has participated at advisory board meetings and symposia organised by Roche/Chugai/Genentech, BMS, Janssen, Sanofi and UCB. MS, FB, and MM declare no conflict.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

REFERENCES

1. **Cronestein BN.** Interleukin-6. A key mediator of systemic and local symptoms in rheumatoid arthritis (abstract). *Bull NYU Hosp Jt Dis* 2007;**65**(Suppl 1):S11–5.
2. [http://www.abstracts2view.com/eular/\(Online\)](http://www.abstracts2view.com/eular/(Online)) (accessed Jan 2012).
3. http://www.rheumatology.org/publications/acr_arhp_annual_meeting.asp (Online) (accessed Jan 2012).
4. <http://www.clinicaltrials.gov> (Online) (accessed Jan 2012).
5. **Wallace BC, Schmid CH, Lau J, et al.** Meta-analyst: software for meta-analysis of binary, continuous and diagnostic data. *BMC Med Res Methodol* 2009;**9**:80ff.
6. **Jadad AR, Moore RA, Carroll D, et al.** Assessing the quality of reports of randomized clinical trials: Is blinding necessary? *Controll Clin Trials* 1996;**17**:1–12.
7. **Moher D, Liberati A, Tetzlaff J, et al., and the PRISMA Group.** Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med* 2009;**151**:264–9.
8. **Jones G, Sebba A, Gu J, et al.** Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. *Ann Rheum Dis* 2010;**69**:88–96.
9. **Choy EH, Isenberg DA, Garrood T, et al.** Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. *Arthritis Rheum* 2002;**46**:3143–50.
10. **Genovese MC, McKay JD, Nasonov EL, et al.** Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. *Arthritis Rheum* 2008;**58**:2968–80.
11. **Smolen JS, Beaulieu A, Rubbert-Roth A, et al.** Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. *Lancet* 2008;**371**:987–97.
12. **Nishimoto N, Hashimoto J, Miyasaka N, et al.** Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. *Ann Rheum Dis* 2007;**66**:1162–7.
13. **Kremer JM, Blanco R, Brzosko M, et al.** Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate. *Arthritis Rheum* 2011;**63**:609–21.
14. **Nishimoto N, Miyasaka N, Yamamoto K, et al.** Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition. *Mod Rheumatol* 2009;**19**:12–19.
15. **Maini RN, Taylor PC, Szechinski J, et al.** Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. *Arthritis Rheum* 2006;**54**:2817–29.
16. **Nishimoto N, Yoshizaki K, Miyasaka N, et al.** Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. *Arthritis Rheum* 2004;**50**:1761–9.
17. **Dougados M, Kissel K, Sheeran T, et al.** Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). *Ann Rheum Dis* 2013;**72**:43–50.
18. **NCT00106535:** A study to assess the effect of tocilizumab and methotrexate on prevention of structural joint damage in patients with moderate to severe active rheumatoid arthritis. 2012. <http://www.clinicaltrials.gov>
19. **Lim MJ, Park SH, Shim SC, et al.** A double-blind, placebo-controlled, multicenter trial of tocilizumab in moderate to severe active RA patients with inadequate response to methotrexate in Korean population (abstract). *Ann Rheum Dis* 2012;**71** (Suppl 3):670.
20. **Emery P, Keystone E, Tony HP, et al.** IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. *Ann Rheum Dis* 2008;**67**:1516–23.
21. **Yazici Y, Curtis JR, Ince A, et al.** Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. *Ann Rheum Dis* 2012;**71**:198–205.
22. **NCT00891020:** A study of tocilizumab in patients with moderate to severe active rheumatoid arthritis who have an inadequate response to or are unable to tolerate biologic and non-biologic disease modifying antirheumatic drugs (DMARDs). 2012. <http://www.clinicaltrial.gov>
23. **Das S, Horton S, Vital E, et al.** Response to abatacept and tocilizumab in patients who had failed rituximab—initial single centre experience (abstract). *Ann Rheum Dis* 2012;**71** (Suppl 3):183.
24. **Smolen JS, Gomez-Reino JJ, Vernon E, et al.** Efficacy of tocilizumab in patients with RA and inadequate response to DMARDs or TNF inhibitors: up to 3.5-year data from ongoing extension studies (abstract). *Ann Rheum Dis* 2010;**69**(Suppl 3):542.

25. **Khraishi M**, Alten R, Gomez-Reino JJ, *et al*. Long-term efficacy of tocilizumab (TCZ) in patients (pts) with rheumatoid arthritis (RA) (abstract). *Ann Rheum Dis* 2011;**70**(Suppl 3):472.
26. **Smolen JS**, Alten RHE, Gomez-Reino J, *et al*. Efficacy of tocilizumab (TCZ) in rheumatoid arthritis (RA): interim analysis of long-term extension trials of up to 2.5 years (abstract). *Ann Rheum Dis* 2009;**68**(Suppl 3):401.
27. **Nishimoto N**, Miyasaka N, Yamamoto K, *et al*. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. *Ann Rheum Dis* 2009;**68**:1580–4.
28. **Nishimoto N, Japanese MRA Study Group for RA Laboratory of Immune Regulation, Wakayama Medical University, Ibaraki-City, Japan**. Drug free remission after cessation of tocilizumab (Actemra) monotherapy (DREAM Study) (abstract). *Ann Rheum Dis* 2010;**69**(Suppl 3):98.
29. **Nishimoto N**. Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis at recurrence (RESTORE Study) (abstract). *Ann Rheum Dis* 2010;**69**(Suppl 3):537.
30. **Sagawa A**. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: the RONIN Study. *Mod Rheumatol* 2011;**21**:352–8.
31. **Aguiar-Lozano M**, Padilla-Ibarra J, Sandoval-Castro C, *et al*. The length of remission and rate of relapse after tocilizumab withdrawal in rheumatoid arthritis patients (abstract). *Ann Rheum Dis* 2012;**71**(Suppl 3):69.
32. **Sibila J**, Graninger W, Östör A, *et al*. Comparison of tocilizumab as monotherapy or with add-on DMARDs in patients with rheumatoid arthritis and an inadequate response to previous treatments: ACT-SURE results (abstract). *Ann Rheum Dis* 2011;**70**(Suppl 3):466.
33. **Weinblatt ME**, Kremer JM, Cush JJ, *et al*. Tocilizumab monotherapy and tocilizumab plus disease-modifying antirheumatic drugs in a US rheumatoid arthritis population with inadequate response to anti-tumor necrosis factor agents (abstract). *ACR* Chicago, USA, 2011. <https://acr.confex.com/acr/webprogram/PresentationNumber:427>.
34. **Weinblatt M**, Kremer J, Cush J, *et al*. Safety of tocilizumab (TCZ) monotherapy and tocilizumab plus DMARDs in a US RA population with inadequate response (IR) to biologics or DMARDs: the ACT-STAR study (abstract). *Ann Rheum Dis* 2011;**70**(Suppl 3):170.
35. **Östör A**, Román Ivorra RA, Wollenhaupt J, *et al*. Comparison of tocilizumab as monotherapy or in combination with non-biological disease-modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) and an inadequate response to anti-TNF agents (abstract). *Ann Rheum Dis* 2012;**71**(Suppl 3):372.
36. **Troum O**, Peterfy C, Olech E, *et al*. Early reductions in synovitis and osteitis with tocilizumab therapy are maintained through week 52: results from the ACT-RAY MRI substudy (abstract). *Ann Rheum Dis* 2011;**70**(Suppl 3):613.
37. **Troum O**, Peterfy C, Kaine J, *et al*. Tocilizumab reduces synovitis within 2 weeks and pre-erosive osteitis within 12 weeks in patients with RA: Results from a multi-site low-field MRI study (abstract). *Ann Rheum Dis* 2010;**69**(Suppl 3):98.
38. **Conaghan PG**, Peterfy CG, DiCarlo J, *et al*. Early reduction in tissue inflammation with tocilizumab as either monotherapy or in combination with methotrexate: 12-week unblinded results from a magnetic resonance imaging substudy of a randomized controlled trial (abstract). *ACR* Chicago, USA, 2011. <https://acr.confex.com/acr/webprogram/PresentationNumber:434>.
39. **Kremer J**, Furst D, Burgos-Vargas R, *et al*. LITHE: tocilizumab (TCZ) inhibits radiographic progression, maintains clinical efficacy in rheumatoid arthritis (RA) patients (pts) at 3 years (abstract). *Ann Rheum Dis* 2011;**70**(Suppl 3):467.
40. **Garnero P**, Mareau E, Thompson E, *et al*. Relationships between changes in biological markers of inflammation and cartilage metabolism and radiological progression in patients with rheumatoid arthritis treated with tocilizumab combined with methotrexate: the LITHE study (abstract). *Ann Rheum Dis* 2009;**68**(Suppl 3):547.
41. **Kume K**, Amano K, Yamada S, *et al*. Tocilizumab monotherapy improves bone mineral density as well as etanercept or adalimumab monotherapy in rheumatoid arthritis (abstract). An open-label, randomized clinical trial. *Ann Rheum Dis* 2011;**70**(Suppl 3):471.
42. **Pierguidi S**, Bertoldi I, Adinolfi A, *et al*. Effects of tocilizumab on bone density and metabolism in patients with active rheumatoid arthritis (abstract). *Ann Rheum Dis* 2012;**71**(Suppl 3):668.
43. **Smolen JS**, Avila JC, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. *Ann Rheum Dis* 2012;**71**:687–93.
44. **Bergman GJ**, Hochberg MC, Boers M, *et al*. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. *Semin Arthritis Rheum* 2010;**39**:425–41.
45. **Yoshida K**, Tokuda Y, Oshikawa H, *et al*. An observational study of tocilizumab and TNF-alpha inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety. *Rheumatology* 2011;**50**:2093–99.
46. **Kaufmann J**, Feist E, Schmidt H, *et al*. Comparison of the efficacy of tocilizumab and TNF inhibitors on the DAS28 in real life conditions in rheumatoid arthritis (RA) patients after DMARD failure (abstract). *ACR* Atlanta, USA, 2012. <http://www.rheumatology.org/apps/MyAnnualMeeting/ExploreMeetingAbstractNumber:1271>.
47. **Kaufmann J**, Roske A. Comparison of tocilizumab and TNF inhibitor therapy in rheumatoid arthritis (abstract). *ACR* 2011, Chicago, USA.
48. **Orme ME**, Fotheringham I, Mitchell SA, *et al*. Systematic review and network meta-analysis of combination therapy for methotrexate-experienced, rheumatoid arthritis patients: analysis of American College of Rheumatology criteria scores 20, 50 and 70 (abstract). *ACR*, Chicago, USA, 2011. <https://acr.confex.com/acr/webprogram/PresentationNumber:2247>.
49. **Schoels M**, Aletaha D, Smolen JS, *et al*. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor alpha inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. PMID: 22294630, *Ann Rheum Dis* 2012;**71**:1303–8.
50. **Leffers HC**, Ostergaard M, Glinborg B, *et al*. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. *Ann Rheum Dis* 2011;**70**:1216–22.
51. **Gabay C**, Emery P, van Vollenhoven R, *et al*. Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 ADACTA trial (abstract). *Ann Rheum Dis* 2012;**71**(Suppl 3):152.
52. **Breedveld FC**, Weisman MH, Kavanaugh AF, *et al*. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis Rheum* 2006;**54**:26–37.
53. **Burmester GR**, Feist E, Kellner H, *et al*. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). *Ann Rheum Dis* 2011;**70**:755–9.
54. **Izumi K**, Kaneko Y, Yasuoka H, *et al*. Efficacy and safety of tocilizumab in patients with rheumatoid arthritis in the presence or absence of previous treatment with biologics and concomitant treatment with methotrexate (abstract). *Ann Rheum Dis* 2012;**71**(Suppl 3):669.
55. **Wakabayashi H**, Oka H, Nishioka Y, *et al*. Do biologics-naïve patients with rheumatoid arthritis respond better to tocilizumab than patients for whom anti-TNF agents have failed? A retrospective study. *Clin Exp Rheumatol* 2011;**29**:314–17.
56. **Nakashima Y**, Kondo M, Harada H, *et al*. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. *Mod Rheumatol* 2010;**20**:343–52.
57. **Yamanaka H**, Tanaka Y, Inoue E, *et al*. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). *Mod Rheumatol* 2011;**21**:122–33.
58. **Takeuchi T**, Tanaka Y, Amano K, *et al*. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients—REACTION 52-week study. *Rheumatology* 2011;**50**:1908–15.
59. **Wakabayashi H**, Hasegawa M, Sudo A, *et al*. Tocilizumab improves treatment outcomes in patients with rheumatoid arthritis for whom anti-TNF agents has failed (abstract). *Ann Rheum Dis* 2012;**71**(Suppl 3):668.
60. **Leffers HC**, Ostergaard M, Glinborg B, *et al*. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. *Ann Rheum Dis* 2011;**70**:1216–22.
61. **Specker C**, Kaufmann J, Vollmer MA, *et al*. Tocilizumab in rheumatoid arthritis—1 year interim analysis of the non-interventional ICHIBAN study (abstract). *Ann Rheum Dis* 2012;**71**(Suppl 3):667.
62. **Navarro-Millán I**, Singh JA, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. *Clin Ther* 2012;**34**:788–802.
63. **Ohta S**, Tsuru T, Terao K, *et al*. A phase I/II study evaluating the safety, pharmacokinetics and clinical response of tocilizumab for subcutaneous administration in patients with rheumatoid arthritis (abstract). *Ann Rheum Dis* 2010;**69**(Suppl 3):543.
64. **Ogata A**, and MUSASHI Study Group. The MUSASHI study: comparison of subcutaneous tocilizumab monotherapy versus intravenous tocilizumab monotherapy: results from a double-blind, parallel-group, comparative phase III non-inferiority study in Japanese patients with rheumatoid arthritis (abstract). *Ann Rheum Dis* 2012;**71**(Suppl 3):373.
65. **Radin AR**, Mellis SJ, Jasson M, *et al*. REGN88/SAR153191, a fully-human interleukin-6 receptor monoclonal antibody, reduces acute phase reactants in patients with rheumatoid arthritis: preliminary observations from Phase 1 studies (abstract). *ACR* Atlanta, USA, 2011. <http://www.rheumatology.org/apps/MyAnnualMeeting/ExploreMeetingAbstractNumber:1121>.
66. **Huizinga TW**, Kivitz AJ, Rell-Bakalarska M, *et al*. Sarilumab for the treatment of moderate-to-severe rheumatoid arthritis: results of a phase 2, randomized, double-blind, placebo-controlled, international study (abstract). *Ann Rheum Dis* 2012;**71**(Suppl 3):60.
67. **Hsu B**. (2631) Results from a 2-Part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, Phase 2 study of sirukumab, a human

- anti-interleukin-6 monoclonal antibody, in active rheumatoid arthritis patients despite methotrexate therapy (abstract). *ACR* Chicago, USA, 2011. <https://acr.confex.com/acr/webprogram/PresentationNumber:2631>.
68. **Hsu B**, Zhou B, Smolen JS, *et al*. Proof-of-concept for CNTO 136, a human anti-interleukin-6 monoclonal antibody, in a multicenter, randomized, double-blind, placebo-controlled, phase 2 study in patients with active rheumatoid arthritis despite methotrexate therapy (abstract). *Ann Rheum Dis* 2011;**70**(Suppl 3):459.
 69. **Hsu B**, Sheng S, Smolen JS, *et al*. Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-il-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy (abstract). *Ann Rheum Dis* 2012;**71**(Suppl 3):188.
 70. **Wendling D**, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. *J Rheumatol* 1993;**20**:259–62.
 71. **Shakib S**, Francis B, Smith J, *et al*. Safety, Pharmacokinetics and pharmacodynamics of ALD518 (BMS-945429), a high-affinity monoclonal antibody directed against interleukin-6 (IL-6) administered by subcutaneous injection: a Phase I trial (abstract). *ACR*, Atlanta, USA, 2011. <http://www.rheumatology.org/apps/MyAnnualMeeting/ExploreMeetingAbstractNumber:1124>.
 72. **Mease P**, Strand V, Shalamberidze L, *et al*. Inhibition of IL-6 with ALD518 improves disease activity in rheumatoid arthritis trials in a randomized, double-blind, placebo-controlled, dose-ranging phase 2 trial (abstract). *Ann Rheum Dis* 2010;**69**(Suppl 3):98.
 73. **Mease P**, Strand V, Shalamberidze L, *et al*. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. *Ann Rheum Dis* 2012;**71**:1183–9.
 74. **NCT01463059**. Efficacy and safety of olokizumab with rheumatoid arthritis with previously failed to Anti-tumor Necrosis Factor (Anti-TNF) therapy. <http://www.clinicaltrials.gov>
 75. **NCT01533714**. The long-term safety and efficacy of olokizumab (CDP6038) with active rheumatoid arthritis. <http://www.clinicaltrials.gov>
 76. **De Benedetti F**, Brunner H, Ruperto N, *et al*. Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis: Efficacy Data from the Placebo-Controlled 12-Week Part of the Phase 3 TENDER Trial (abstract). *Abstract Supplement Abstracts of the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting*; 6–11 November, 2010, Atlanta, Georgia, Arthritis & Rheumatism, Vol. 62.
 77. **De Benedetti F**, Brunner H, Ruperto N, *et al*. Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data (abstract). *Ann Rheum Dis* 2011;**70**(Suppl 3):67.
 78. **De Benedetti F**, Brunner H, Ruperto N, *et al*. Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): 2-year data from TENDER, a phase 3 clinical trial (abstract). *Ann Rheum Dis* 2012;**71**(Suppl 3):425.
 79. **Yokota S**, Imagawa T, Takei S, *et al*. Clinical remission in children with systemic juvenile idiopathic arthritis receiving tocilizumab treatment—analysis from phase II and phase III extension trials (abstract). *Ann Rheum Dis* 2010;**69**(Suppl 3):627.
 80. **Kubota T**, Yamasaki Y, Yasumura J, *et al*. Can long-term use of tocilizumab induce drug-free remission in systemic juvenile idiopathic arthritis refractory to steroid therapy? (abstract) *ACR* Chicago, USA, 2011. <https://acr.confex.com/acr/webprogram/PresentationNumber:267>.
 81. **Imagawa T**, Yokota S, Mori M, *et al*. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. *Mod Rheumatol* 2012;**22**:109–15.
 82. **Guillen Astet CA**, Anton Pages F, Sifuetes Giraldo WA, *et al*. Juvenile idiopathic arthritis on biologic treatment: new onset adverse events. A retrospective study (abstract). *Ann Rheum Dis* 2010;**69**(Suppl 3):708.
 83. **Alexeeva E**, Denisova R, Valieva , *et al*. Safety and efficacy tocilizumab therapy in children with juvenile idiopathic arthritis (abstract). *Ann Rheum Dis* 2010;**69**(Suppl 3):708.
 84. **Horneff G**, Foeldvari I, Kuemmerle-Deschner J, *et al*. Switching of biologics in juvenile idiopathic arthritis (abstract). *Ann Rheum Dis* 2011;**70**(Suppl 3):402.
 85. **Pontikaki I**, Shahi E, Romano M, *et al*. Tocilizumab in 12 young adults affected by juvenile idiopathic arthritis (JIA) non responsive to other biologic agents: preliminary data (abstract). *Ann Rheum Dis* 2011;**70**(Suppl 3):403.
 86. **Singh JA**, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. *Cochrane Database Syst Rev* 2010;(7):CD008331. doi:10.1002/14651858.CD008331.pub2
 87. **Schiff MH**, Kremer JM, Jahreis A, *et al*. Integrated safety in tocilizumab clinical trials. *Arthritis Res Ther* 2011;**13**:R141.
 88. **Takeuchi T**, Harigai M, Inokuma S, *et al*. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan interim analysis of 6424 patients (abstract). *Ann Rheum Dis* 2011;**70**(Suppl 3):610.
 89. **Yamanaka H**, Harigai M, Inokuma S, *et al*. The advantage of early intervention by tocilizumab for rheumatoid arthritis—full analysis of all-case postmarketing surveillance in 7,901 patients in Japan (abstract). *Ann Rheum Dis* 2012;**71**(Suppl 3):184.
 90. **Koike T**, Harigai M, Inokuma S, *et al*. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. *Ann Rheum Dis* 2011;**70**:2148–51.
 91. **Singh JA**, Wells GA, Christensen R, *et al*. Adverse effects of biologics: a network meta-analysis and Cochrane overview (review). *Cochrane Database Syst Rev*: 2011: CD008794. doi:10.1002/14651858.CD008794.pub2
 92. **Ishikawa H**, Kanamono T, Kojima T, *et al*. Treatment of young female patients with rheumatoid arthritis using biological agents—results from 6 years of surveillance of clinical practice in Japanese TBC registry for the patients with rheumatoid arthritis using biologics (abstract). *Ann Rheum Dis* 2010;**69**(Suppl 3):679.
 93. **Ishikawa H**, Kojima T, Kanamono T, *et al*. Pregnancy in women with rheumatoid arthritis receiving biologic agents—results from 7 years of surveillance of clinical practice in Japanese TBC registry for the patients with rheumatoid arthritis using biologics (abstract). *Ann Rheum Dis* 2011;**70**(Suppl 3):256.
 94. **Rubbert-Roth A**, Goupille PM, Moosavi S, *et al*. First experiences with pregnancies in RA patients (pts) receiving tocilizumab therapy (abstract). *ACR* Atlanta, USA, 2010. <http://www.rheumatology.org/apps/MyAnnualMeeting/ExploreMeetingAbstractNumber:384>.

Corrections

Schoels MM, van der Heijde D, Breedveld FC, *et al.* Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. *Ann Rheum Dis* 2013;**72**:583–9. The author ‘Miho M Murikama’ should be ‘Miho Murakami.’

Ann Rheum Dis 2013;**72**:1110. doi:10.1136/annrheumdis-2012-202470corr1